Six children in palliative care saw fewer seizures and less pain with medical cannabis

All six patients experienced a reduction in seizure frequency (with variable extent) after starting medical cannabis. Pain also improved based on caregiver evaluation, and analgesic medication use decreased. Side effects were mild and transient: drowsiness, euphoria, restlessness, and tachycardia. No treatment was discontinued and no overdoses occurred.

Case series of six pediatric palliative care patients at an Italian center who received titrated plant extract of cannabis sativa for one year. Caregivers reported changes in seizure frequency, seizure intensity, and pain. Adverse events were monitored throughout.

Children in palliative care often have treatment-resistant epilepsy and chronic pain with limited therapeutic options. This case series provides initial evidence that medical cannabis may be a tolerable and beneficial addition to their care.

Pediatric palliative care represents a population where quality of life is the primary goal and standard treatments have often failed. The tolerability and apparent benefit seen here supports further investigation in this vulnerable group.

Case series with only 6 patients and no control group. Outcomes were caregiver-reported without blinding. Variable extent of seizure reduction makes it hard to quantify the benefit precisely. No standardized pain assessment tools described.